Revenue remains highly volatile, evidenced by a 191.9% year-over-year growth in 2026Q1 driven by non-recurring milestones rather than sustainable product sales.
| Sales/Revenue | 92.59M | 75.56M | 10.12M | 1.7M | 6.19M | 1.51M | 1.72M | 2.91M | 1.05M | 1.69M | 1.21M | 94.11K |
| Revenue Growth % | 927.51% | 646.68% | 496% | -72.59% | 311.02% | -12.13% | -41.02% | 178.19% | -38.26% | 39.69% | 1187.83% | - |
| Cost of Goods Sold | 102.95M | 96.59M | 141.02M | 0 | 0 | 0 | 134.89M | 105.42M | 48.3M | 1.01M | 478K | 0 |
| COGS % of Revenue | - | 127.83% | 1393.48% | - | - | - | 7865.19% | 3625.1% | 4620.4% | 59.6% | 39.44% | - |
| Gross Profit | -10.36M | -21.03M | -130.9M | 1.7M | 6.19M | 1.51M | -133.17M | -102.51M | -47.25M | 684K | 734K | 94.11K |
| Gross Margin % | -11.19% | -27.83% | -1293.48% | 100% | 100% | 100% | -7765.19% | -3525.1% | -4520.4% | 40.4% | 60.56% | 100% |
| Gross Profit Growth % | - | 83.93% | -7809.07% | -72.59% | 311.02% | 101.13% | -29.91% | -116.94% | -7008.43% | -6.81% | 679.92% | - |
| Operating Expenses | 254.35M | 260.41M | 110.53M | 181.4M | 149.09M | 141.88M | 169.96M | 145.07M | 41.48M | 25.11M | 15.59M | 8.2M |
| OpEx % of Revenue | - | 344.62% | 1092.15% | 10683.1% | 2406.96% | 9414.8% | 9910.2% | 4988.65% | 3968.39% | 1483.22% | 1286.14% | 8713.76% |
| Selling, General & Admin | 142.24M | 131.82M | 0 | 46.74M | 31.9M | 31.86M | 34.97M | 39.45M | 16.85M | 9.1M | 5.15M | 6.04M |
| SG&A % of Revenue | - | 174.45% | - | 2752.94% | 515% | 2114.47% | 2039.18% | 1356.67% | 1611.51% | 537.45% | 425.08% | 6422.09% |
| Research & Development | 112.11M | 128.59M | 158.14M | 130.48M | 117.35M | 110.84M | 134.99M | 105.62M | 24.64M | 16.01M | 10.44M | 2.17M |
| R&D % of Revenue | - | 170.17% | 1562.61% | 7684.39% | 1894.64% | 7354.94% | 7871.02% | 3631.98% | 2356.89% | 945.78% | 861.06% | 2308.54% |
| Other Operating Expenses | 1 | 0 | -47.61M | 4.17M | -166K | -823K | 0 | 0 | 3.97M | -46K | -26K | 0 |
| Operating Income | -264.71M | -281.44M | -241.43M | -179.7M | -142.89M | -140.37M | -303.13M | -247.58M | -57.53M | -23.42M | -14.38M | -8.11M |
| Operating Margin % | -285.9% | -372.45% | -2385.63% | -10583.1% | -2306.96% | -9314.8% | -17675.39% | -8513.76% | -5503.74% | -1383.22% | -1186.14% | -8613.76% |
| Operating Income Growth % | - | -16.57% | -34.35% | -25.76% | -1.79% | 53.69% | -22.44% | -330.33% | -145.68% | -62.9% | -77.34% | - |
| EBITDA | -251.72M | -271.6M | -233.71M | -173.14M | -135.47M | -131.92M | -297.57M | -243.02M | -55.82M | -22.41M | -13.9M | -4.47M |
| EBITDA Margin % | -271.86% | -359.43% | -2309.39% | -10196.47% | -2187.13% | -8753.55% | -17350.79% | -8356.81% | -5340.26% | -1323.63% | -1146.7% | -4749.84% |
| EBITDA Growth % | 40.63% | -16.21% | -34.99% | -27.8% | -2.69% | 55.67% | -22.45% | -335.33% | -149.11% | -61.24% | -210.91% | - |
| D&A (Non-Cash Add-back) | 13M | 9.84M | 7.72M | 6.57M | 7.42M | 8.46M | 5.57M | 4.56M | 1.71M | 1.01M | 478K | 3.64M |
| EBIT | -261.16M | -281.44M | -240.79M | -163.34M | -139.66M | -140.93M | -168.15M | -141.96M | -52.03M | -23.42M | -14.38M | -8.11M |
| Net Interest Income | -22.3M | -17.73M | 23.06M | -31.56M | -7.2M | -843K | 536K | 2.54M | 4.11M | 84K | 75K | 0 |
| Interest Income | 22.14M | 19.02M | 32.35M | 13.51M | 1.71M | 262K | 536K | 2.54M | 4.12M | 84K | 75K | 7.93K |
| Interest Expense | 44.43M | 36.76M | 9.29M | 45.07M | 8.9M | 1.1M | 0 | 0 | 12.67K | 0 | 0 | 0 |
| Other Income/Expense | -23.51M | -15.41M | 22.29M | -28.7M | -5.67M | -1.66M | 136.88M | 138.89M | 6.91M | 38K | 49K | 7.93K |
| Pretax Income | -288.22M | -296.85M | -219.13M | -208.4M | -148.57M | -142.04M | -166.26M | -108.69M | -36.33M | -23.38M | -14.33M | -8.1M |
| Pretax Margin % | -311.29% | -392.84% | -2165.36% | -12273.38% | -2398.56% | -9425.22% | -9694.29% | -3737.62% | -3475.09% | -1380.98% | -1182.1% | -8605.34% |
| Income Tax | 609.26K | -8.65M | 1.53M | -19K | 272K | 58K | -24.16M | 15.16M | -5.21M | -3.65M | -1.78M | -634.51K |
| Effective Tax Rate % | -0.21% | 2.91% | -0.7% | 0.01% | -0.18% | -0.04% | 14.53% | -13.95% | 14.35% | 15.62% | 12.4% | 7.83% |
| Net Income | -288.83M | -288.2M | -220.66M | -208.38M | -148.84M | -142.1M | -142.09M | -123.85M | -31.11M | -19.73M | -12.55M | -7.46M |
| Net Margin % | -311.95% | -381.4% | -2180.45% | -12272.26% | -2402.95% | -9429.06% | -8285.36% | -4258.91% | -2976.49% | -1165.21% | -1035.48% | -7931.14% |
| Net Income Growth % | -21.29% | -30.61% | -5.89% | -40.01% | -4.75% | -0% | -14.73% | -298.04% | -57.73% | -57.19% | -68.14% | - |
| Net Income (Continuing) | -288.83M | -288.2M | -220.66M | -208.38M | -148.84M | -142.1M | -142.09M | -123.85M | -44.75M | -19.73M | -12.55M | -7.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.09 | -1.08 | -0.87 | -1.20 | -1.57 | -1.97 | -2.76 | -2.88 | -0.99 | -1.43 | -0.91 | -0.54 |
| EPS Growth % | -22.47% | -24.14% | 27.5% | 23.57% | 20.3% | 28.62% | 4.17% | -190.91% | 30.77% | -57.14% | -68.52% | - |
| EPS (Basic) | - | -1.08 | -0.87 | -1.20 | -1.57 | -1.97 | -2.76 | -2.88 | -0.99 | -1.43 | -0.91 | -0.54 |
| Diluted Shares Outstanding | 266.14M | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M | 51.56M | 43.07M | 31.56M | 13.78M | 13.78M | 13.78M |
| Basic Shares Outstanding | 266.14M | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M | 51.56M | 43.07M | 31.56M | 13.78M | 13.78M | 13.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Pre-commercial clinical execution risk
As reported in financial statements, Autolus's revenue trajectory remains highly volatile, characterized by a 191.9% year-over-year increase in 2026Q1, which reflects the recognition of non-recurring milestone payments rather than sustainable product sales, leaving the company's long-term growth durability entirely dependent on successful commercialization of its lead candidate.
The absence of recurring revenue streams highlights the company's current status as a pre-commercial entity reliant on strategic partnerships. Investors should monitor the timing of future milestone recognition, as these figures do not indicate underlying market demand for the company's cell therapy platform.
Based on reported figures, Autolus continues to face significant margin volatility, with gross margins fluctuating from a positive 82.1% in 2024Q1 to a negative 4.3% in 2025Q4, illustrating the high fixed-cost burden associated with maintaining specialized cell-therapy manufacturing infrastructure ahead of any meaningful commercial product revenue.
The negative gross margins suggest that the costs associated with 'The Nucleus' facility are currently outpacing the revenue generated from clinical-stage activities. Achieving sustainable margin expansion will likely require a transition to high-volume commercial production to leverage existing fixed overheads effectively.
According to recent SEC filings, Autolus's operating expenses remain elevated, with R&D and SG&A costs totaling $61.2 million in 2026Q1, reflecting the substantial capital commitment required to sustain clinical trial execution and commercial readiness activities in a highly competitive biotechnology landscape.
The consistent level of R&D spending indicates a management focus on pipeline advancement, yet this strategy necessitates continuous capital infusion. The lack of expense discipline relative to revenue generation warrants further investigation into the company's long-term cash runway and potential for future dilutive financing.
As indicated by the income statement data, the company's reliance on non-operating income and milestone-based revenue creates a precarious financial profile, where the $71.6 million net loss in 2026Q1 underscores the significant risk that current capital resources may be insufficient to reach commercial self-sufficiency.
Short-sellers may focus on the disconnect between the company's high valuation and its persistent cash burn. The reliance on complex financing arrangements, such as the Blackstone deal, suggests that future equity dilution may be inevitable if commercial milestones are not met in a timely manner.
Quick answers to the most common questions about buying AUTL stock.
For fiscal year 2025, Autolus Therapeutics plc (AUTL) reported total revenue of $75.6M. This represents a 80191.8% increase compared to $0.1M in 2015.
Autolus Therapeutics plc (AUTL) reported a net loss of $288.2M for the fiscal year ending 2025.
Autolus Therapeutics plc (AUTL) reported an operating income of $-281.4M, resulting in an operating profit margin of -372.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Autolus Therapeutics plc (AUTL) generated $-21.0M in gross profit for the year, representing a gross profit margin of -27.8%. This demonstrates the company's core pricing power and production efficiency.